Los GLP-1 tampoco deberan verse como soluciones a corto plazo, dice el editorial
How This Blind Spot Leads Directly Into the Next Crisis If we cannot explain how GLP-1 agonists exert their multi-system effects, then we cannot reliably determine who benefits from them, why certain responses emerge, or which biological signatures distinguish durable responders from partial responders, early plateauers, non-responders, or individuals at risk for muscle loss, inflammatory rebound, or neuroprotective divergence
Research into the efficacy of GLP-1 drugs found that, in a clinical trial setting, Semaglutide (Ozempic and Wegovy) could result in a 14.9% reduction in body weight over the course of 68 weeks
Gastric microbiota: tracing the culprit
Circ Res 2021, 128(1): 136-149
Living without a gallbladder can require some adjustments to your diet